Mabwell Bioscience Clears All Agenda Items at 2026 Third EGM; Approves EY as Auditor and New H-Share Issuance Mandate

Bulletin Express06-18

The 2026 third extraordinary general meeting (EGM) of Mabwell (Shanghai) Bioscience Co., Ltd. convened on 18 June 2026 in Shanghai, with all directors present in person or electronically. The meeting, legally constituted under PRC regulations and the company’s Articles of Association, covered remuneration policies, auditor appointment and share-issuance authorities, alongside board elections.

A total of 446.73 million shares were issued as of the record date, including 399.60 million A Shares and 47.13 million H Shares. After deducting 1.19 million treasury A Shares without voting rights, 445.54 million shares were entitled to vote. No shareholders were required to abstain, and voting was conducted by poll, combining on-site and online ballots for A shareholders. Tricor Investor Services acted as scrutineer for H-share voting.

Key resolutions and corresponding approval rates were as follows: • Remuneration management system for directors and senior management: 99.92% in favour (205.07 million votes). • 2026 director remuneration plan: 99.92% in favour (205.07 million votes). • Appointment of Ernst & Young as H-share auditor for 2026: 99.80% in favour (204.82 million votes). • General mandate to issue additional H Shares: 99.79% in favour (204.81 million votes).

Board composition was refreshed under cumulative voting: • Executive directors elected – Tang Chunshan, Liu Datao, Wu Hai and Hua Jun – each secured at least 99.78% support, with Liu Datao receiving the highest approval at 99.86%. • Independent non-executive directors elected – Qin Zhengyu, Zhou Rui, Li Fan and Wang Fang – garnered between 99.09% and 99.80% approval, with Wang Fang obtaining the top vote at 99.80%.

Merits & Tree Law Offices, serving as PRC legal adviser, confirmed the meeting procedures and poll results complied with all statutory and constitutional requirements, declaring the outcomes valid.

All eight resolutions therefore stand approved, authorising the updated remuneration framework, director compensation for 2026, EY’s auditor appointment, a new H-share issuance mandate and the refreshed board lineup.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment